Keira Bell, Bell v Tavistock and detransition in the UK

What did the Bell v Tavistock litigation decide, and what is known about detransition in Britain?

Keira Bell became the public face of a legal challenge to the former Tavistock and Portman NHS Foundation Trust’s Gender Identity Development Service (GIDS). Bell had received puberty-suppressing medication as an adolescent, later took testosterone and underwent surgery, and subsequently detransitioned. Together with “Mrs A”, the mother of a teenage girl, she sought judicial review of the lawfulness of the consent arrangements used when children and young people were referred for puberty blockers.

Background

Keira Bell became the public face of a legal challenge to the former Tavistock and Portman NHS Foundation Trust’s Gender Identity Development Service (GIDS). Bell had received puberty-suppressing medication as an adolescent, later took testosterone and underwent surgery, and subsequently detransitioned. Together with “Mrs A”, the mother of a teenage girl, she sought judicial review of the lawfulness of the consent arrangements used when children and young people were referred for puberty blockers.

The case was not a damages claim, and it did not decide whether Bell had personally been negligently treated. Nor did it decide the general clinical merits of puberty blockers. The central legal issue was narrower but important: what must a child understand, retain and weigh in order to give legally valid consent under the established Gillick competence principle. The High Court itself stressed that it was deciding consent, not the balance of benefits and harms of treatment. (High Court, 2020). ([judiciary.uk](https://www.judiciary.uk/wp-content/uploads/2020/12/Bell-v-Tavistock-Judgment.pdf?page=15))

The litigation occurred against a backdrop of rapidly rising referrals to GIDS, weak long-term outcome data and growing professional disagreement about the appropriate assessment and medical pathway for distressed children. The High Court recorded that GIDS referrals had risen from 97 in 2009 to 2,519 in 2018, and that 76 per cent of referrals in 2019 were female. Those figures were part of the factual context before the court, not findings that any particular explanation for the change was proven. (High Court, 2020). ([judiciary.uk](https://www.judiciary.uk/wp-content/uploads/2020/12/Bell-v-Tavistock-Judgment.pdf?page=15))

What the documents say

The High Court decision

In December 2020, the Divisional Court held that a child considering puberty blockers would need to understand not only the immediate effects of the drugs, but also the likelihood that treatment could form part of a pathway towards cross-sex hormones and possible surgery; implications for fertility and sexual function; potential effects on future relationships; unknown physical consequences; and the uncertainty of the evidence base. The court said it was “highly unlikely” that a child aged 13 or under could be competent to consent, and “very doubtful” that a 14- or 15-year-old could understand and weigh the long-term risks and consequences. For 16- and 17-year-olds, it recognised the statutory presumption of capacity but said clinicians might regard court authorisation as appropriate. (High Court, 2020). ([judiciary.uk](https://www.judiciary.uk/wp-content/uploads/2020/12/Bell-v-Tavistock-Clinic-and-ors-Summary.pdf))

This was not, however, a blanket legal ban on puberty blockers for under-16s. The High Court held that the Trust’s written policies were not unlawful, while issuing a declaration and guidance about the information relevant to competence. That distinction became decisive on appeal.

The Court of Appeal and Supreme Court

On 17 September 2021, the Court of Appeal allowed Tavistock’s appeal. It held that, because the Divisional Court had found Tavistock’s policies and practices lawful, it should not have made the declaration or provided general guidance on competence and court involvement. The Court of Appeal set the declaration aside and dismissed the judicial-review claim. It did not hold that all children can consent to blockers; rather, it restored the ordinary legal position that Gillick competence is assessed on the facts of the individual case by clinicians, subject to the ordinary law and the possibility of court involvement where a genuine dispute requires it. (Court of Appeal, 2021). ([bailii.org](https://www.bailii.org/cgi-bin/format.cgi?doc=%2Few%2Fcases%2FEWCA%2FCiv%2F2021%2F1363.html&query=%28title%3A%28+bell+%29%29+AND+%28title%3A%28+v+%29%29+AND+%28title%3A%28+tavistock+%29%29&utm_source=openai))

The Court of Appeal also acknowledged the “difficulties and complexities” of consent to puberty blockers and cross-sex hormones. It said clinicians must take great care to ensure that consent from child and parents is properly informed by advantages, disadvantages, evolving research and long-term consequences. That observation is significant, but it is not a judicial endorsement of any particular clinical model. (Court of Appeal, 2021). ([bailii.org](https://www.bailii.org/cgi-bin/format.cgi?doc=%2Few%2Fcases%2FEWCA%2FCiv%2F2021%2F1363.html&query=%28title%3A%28+bell+%29%29+AND+%28title%3A%28+v+%29%29+AND+%28title%3A%28+tavistock+%29%29&utm_source=openai))

Bell and the second claimant sought permission to appeal to the UK Supreme Court. On 28 April 2022, the Supreme Court refused permission on the ground that the application did not raise an arguable point of law. The Court of Appeal judgment therefore remains the final legal outcome of the litigation. (UK Supreme Court, 2022). ([supremecourt.uk](https://supremecourt.uk/news/permission-to-appeal-april-and-may-2022))

Detransition and the NHS record

“Detransition” does not have a single universally accepted meaning. NHS England uses it for a process in which a person who has undergone a gender transition subsequently discontinues or reverses aspects of it, often alongside a changed understanding of sex or gender. The NHS definition expressly says that regret is not required: a person may detransition with or without regret. (NHS England, 2025). ([england.nhs.uk](https://www.england.nhs.uk/long-read/call-for-evidence-a-clinical-pathway-for-adults-who-have-previously-undergone-a-gender-transition-and-who-wish-to-detransition/?utm_source=openai))

What is known in Britain is limited. There is no published, comprehensive UK register that can establish a reliable national incidence of detransition, distinguish stopping treatment from retransition, or follow all former GIDS patients into adulthood. The Cass Review therefore did not offer a definitive UK percentage. It recommended that NHS England provide for people considering detransition, including those who do not wish to return to the services involved in their transition. (Cass Review, 2024).

NHS England accepted that there was no defined clinical pathway for people considering detransition and committed to examine incidence, reasons, support needs and workforce requirements. In 2025 it conducted lived-experience engagement and then sought evidence from clinicians to inform a national service specification. This is an important institutional admission: Britain has lacked both a reliable outcome-recording system and a coherent route of care for patients who stop or reverse transition. (NHS England, 2024; NHS England, 2025). ([england.nhs.uk](https://www.england.nhs.uk/long-read/children-and-young-peoples-gender-services-implementing-the-cass-review-recommendations/))

The positions

Supporters of the former affirmative model argue that puberty blockers can relieve acute distress for carefully selected young people, that treatment decisions must remain individualised, and that blanket restrictions risk worsening distress for transgender-identifying adolescents. They point to the Court of Appeal’s rejection of a general judicial presumption about competence and argue that clinicians, not courts, should ordinarily assess consent.

Those who support a more cautious, gender-critical approach argue that a child cannot meaningfully consent to a medical pathway without being able to weigh its likely onward trajectory, possible loss of fertility and sexual function, and uncertainties in the evidence. They also argue that the former service placed too much emphasis on asserted identity while insufficiently investigating autism, mental-health problems, trauma, sexual orientation and other factors that may be clinically relevant.

The Cass Review did not adopt either slogan. It concluded that the evidence base for medical interventions in this population was weak, called for holistic assessment and follow-up, and recommended research capable of producing better outcome data. NHS England subsequently closed GIDS and moved towards regional services connected to paediatrics, mental health and local care. (Cass Review, 2024; NHS England, 2024). ([england.nhs.uk](https://www.england.nhs.uk/long-read/nhs-englands-response-to-the-final-report-of-the-independent-review-of-gender-identity-services-for-children-and-young-people/))

Interpretation

Beyond Gender’s reading is that Bell v Tavistock is often misreported by both sides. It did not establish a permanent legal rule that under-16s cannot consent to puberty blockers. The High Court’s declaration was overturned. Equally, the appeal did not settle the ethical or clinical question, and it did not establish that the former Tavistock pathway was safe, evidence-based or appropriately cautious.

The lasting importance of Bell is evidential and institutional. The High Court brought into public view the demanding information that valid consent would require where a treatment may lead towards more consequential interventions. Its concern about missing data, uncertain evidence and the relationship between blockers and later hormones anticipated issues subsequently examined by the Cass Review.

In this site’s view, detransition should neither be denied because it is politically inconvenient nor inflated into a claim that every transition ends in regret. The defensible conclusion is narrower: the NHS did not collect the long-term data needed to know the true rate, and it failed for too long to provide a distinct care pathway for people whose needs changed after transition. That is a patient-safety failure, particularly for people who began medical intervention when young.

Open questions

The most important unanswered question is longitudinal: what happens over years, not months, to children referred to gender services, including those who receive no medical treatment, those who take puberty blockers or hormones, those who proceed to surgery, those who discontinue treatment, and those who detransition or retransition? NHS England has taken responsibility for a data-linkage study involving former GIDS patients and adult data, but meaningful published outcomes remain essential. (NHS England, 2024). ([england.nhs.uk](https://www.england.nhs.uk/long-read/children-and-young-peoples-gender-services-implementing-the-cass-review-recommendations/))

There are also practical questions. Will a detransition pathway include endocrine care, fertility advice, reconstructive and sexual-health support, psychological therapy and treatment for co-existing conditions? Will patients be able to access help without returning to the clinicians or organisations they associate with an unwanted transition? And will the NHS publish figures and definitions robust enough to distinguish cessation caused by side effects, external pressure, changed identity, dissatisfaction with outcomes and retransition?

For parents, clinicians and journalists, the essential discipline is to keep the legal record and the clinical evidence separate. Bell’s final legal outcome concerns the proper limits of judicial guidance in a consent case. The later NHS reforms concern evidence, service design and safeguarding. Neither question can responsibly be reduced to a campaign slogan.

On the UK timeline

Episodes on this subject

From Gay Man to Transwoman... and Back Again | Michael Kerr

Detransitioning - Discomfort Before Something Greater | Soren Aldaco

detrans.ai: A Counter Narrative | Peter James Steven